Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs

China’s NMPA approved Sanofi’s Qfitlia (fitusiran) for routine prophylaxis in adults and adolescents (12+) with severe hemophilia A and Cablivi (caplacizumab) for acquired/immune-mediated TTP (12+, ≥40 kg), marking Sanofi’s fourth and fifth China approvals this year after Tzield and Sarclisa. Qfitlia’s approval is supported by ATLAS Phase 3 data showing a 71% reduction in annualized bleeding rate (ABR) versus on-demand clotting factor in patients without inhibitors and a 73% reduction versus bypassing agents in those with inhibitors, median observed ABRs of 3.8 (without inhibitors) and 1.9 (with inhibitors) in the open-label extension, and broad adoption of a six-injection-per-year regimen; hemophilia affects >40,000 people in China. Cablivi, used with plasma exchange and immunosuppression, addresses roughly 2,700 annual Chinese aTTP cases; the approvals expand Sanofi’s rare-hematology franchise in China and coincide with a modest stock uptick (SNY +1.31% at $48.89 at publication), underscoring regulatory momentum and potential commercial upside in specialty care.

Analysis

China's NMPA approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis in adolescents (12+) and adults with severe hemophilia A and Cablivi (caplacizumab) for acquired/immune-mediated TTP in patients 12+ weighing ≥40 kg, representing Sanofi's fourth and fifth China approvals this year following Tzield and Sarclisa. Sanofi shares traded up modestly (SNY +1.31% to $48.89 at publication), consistent with the provided sentiment that regulatory momentum is viewed positively but not yet transformational.

Qfitlia's approval is supported by ATLAS Phase 3 data showing a 71% reduction in annualized bleeding rate (ABR) versus on-demand clotting factor for patients without inhibitors and a 73% ABR reduction versus bypassing agents for patients with inhibitors; median observed ABRs in the open-label extension were 3.8 (without inhibitors) and 1.9 (with inhibitors). Nearly 47% of patients experienced 0–1 bleeds, 31% had zero bleeds, nearly 80% were on a six-injection-per-year regimen and 94% achieved target antithrombin levels with 0–1 dose adjustments, indicating low-frequency dosing and strong on-study adherence.

Cablivi, the first Nanobody targeted therapy for aTTP in China, is intended for use with plasma exchange and immunosuppression to inhibit vWF-platelet interactions and prevent microthrombi; roughly 2,700 aTTP cases are diagnosed annually in China while hemophilia affects more than 40,000 people. The approvals expand Sanofi's rare-hematology franchise and create potential specialty-care revenue in China, but the market's muted stock reaction suggests investors are weighing limited near-term earnings impact given the relatively small patient populations and remaining execution variables such as launch pace, payer access and real-world uptake.

Key Decisions for Investors

• Consider a modest tactical increase in SNY exposure to capture upside from consecutive China approvals, but size the position conservatively given narrow patient populations and execution risk
• Monitor early commercial KPIs closely—prescription volumes, conversion to the six-injection regimen, real-world ABR outcomes and hospital adoption for Cablivi—to validate clinical trial durability and revenue potential
• Watch Chinese pricing and reimbursement developments and initial sales disclosures for Qfitlia and Cablivi as primary catalysts that will determine whether approvals translate into material top-line contribution
• Maintain a neutral-to-cautious stance until launch traction is visible; if uptake and pricing prove favorable, consider adding exposure or removing hedges, whereas disappointing launch metrics should prompt trimming or hedging